Mixed results for additional immunotherapy to standard care in stage III NSCLC
Different combinations of immunotherapy agent and radiotherapy or chemoradiotherapy were tested in some patient populations in two studies
Neoadjuvant immunotherapy sets a new standard in stage III melanoma
Next steps for research include personalising regimens and learning how to predict response and toxicity
New data show promise in using liquid biopsies to tailor immunotherapy
Studies explore the prognostic and predictive values of circulating DNA tumour fraction and single-cell RNA sequencing of peripheral blood mononuclear cells
Studies shed new light on the role of the gut microbiome in immunotherapy toxicity
Results underline the need to further characterise dysbiosis, and to develop diagnostic and actionable tools for mainstream integration
Immunotherapy added to radiotherapy does not improve outcomes in early-stage NSCLC
A lack of benefit coupled with increased toxicity was reported in patients with stage I/II inoperable disease in the KEYNOTE-867 trial
Are we close to personalise immunotherapy?
According to the 2024 ESMO Immuno-Oncology Awardee, Ton Schumacher, tackling the T-cell receptor challenge with vast datasets and cutting-edge high-throughput methods may pave the way for advances in the field
Real-world evidence has a place in cancer immunotherapy
However, some challenges still limit its implementation in clinical practice
Targeting claudins in pancreatic adenocarcinoma is promising, early-phase findings suggest
Study confirms favourable safety profiles and encouraging efficacy of an anti-claudin 18.2 antibody-drug conjugate
Immunotherapy combinations consolidate their place in the first-line treatment of unresectable hepatocellular carcinoma
Promising new data are presented for nivolumab plus ipilimumab and the single tremelimumab regular interval durvalumab regimen in Asian patients and those with impaired liver function
Short durvalumab infusions appear to be safe for the first-line treatment of advanced biliary tract cancer
Early results from a phase III trial support 30-minutes infusions of immunotherapy with some advantages for patients